BR112022018730A2 - Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformante - Google Patents

Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformante

Info

Publication number
BR112022018730A2
BR112022018730A2 BR112022018730A BR112022018730A BR112022018730A2 BR 112022018730 A2 BR112022018730 A2 BR 112022018730A2 BR 112022018730 A BR112022018730 A BR 112022018730A BR 112022018730 A BR112022018730 A BR 112022018730A BR 112022018730 A2 BR112022018730 A2 BR 112022018730A2
Authority
BR
Brazil
Prior art keywords
interleukin
recombinant
analog
nucleic acid
expression vector
Prior art date
Application number
BR112022018730A
Other languages
English (en)
Inventor
Lim Oh Euh
Yun Kim Sang
Ho Heo Yong
Young Kim Jin
Rong Park Cho
Sub Park Jun
soo ryu Hyun
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112022018730A2 publication Critical patent/BR112022018730A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANÁLOGO DE INTERLEUCINA-2, ÁCIDO NUCLEICO ISOLADO, VETOR DE EXPRESSÃO RECOMBINANTE E TRANSFORMANTE. A presente invenção refere-se a alterações em receptores alfa de interleucina-2 e análogos de interleucina-2 com afinidade de ligação aumentada para receptores beta de interleucina-2.
BR112022018730A 2020-03-31 2021-03-31 Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformante BR112022018730A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200039476 2020-03-31
PCT/KR2021/004028 WO2021201615A1 (ko) 2020-03-31 2021-03-31 신규한 면역 활성 인터루킨 2 아날로그

Publications (1)

Publication Number Publication Date
BR112022018730A2 true BR112022018730A2 (pt) 2022-11-01

Family

ID=77930406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018730A BR112022018730A2 (pt) 2020-03-31 2021-03-31 Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformante

Country Status (16)

Country Link
US (2) US11746137B2 (pt)
EP (1) EP4130027A1 (pt)
JP (2) JP2023515247A (pt)
KR (2) KR102545250B1 (pt)
CN (1) CN115427437B (pt)
AR (1) AR121713A1 (pt)
AU (2) AU2021202825B2 (pt)
BR (1) BR112022018730A2 (pt)
CA (1) CA3169564A1 (pt)
CL (1) CL2022002562A1 (pt)
IL (1) IL295826A (pt)
MX (1) MX2022011893A (pt)
PE (1) PE20221759A1 (pt)
TW (1) TW202204387A (pt)
WO (1) WO2021201615A1 (pt)
ZA (1) ZA202209565B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
KR102445492B1 (ko) * 2021-12-24 2022-09-21 엔케이젠 주식회사 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법
WO2023245097A2 (en) * 2022-06-16 2023-12-21 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3285989A (en) 1987-11-25 1989-06-14 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
CA2019714A1 (en) * 1989-06-27 1990-12-27 Richard A. Chizzonite Process for the determination of interleukins
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
PL211886B1 (pl) * 1999-10-04 2012-07-31 Novartis Vaccines & Diagnostic Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN1930300A (zh) 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2007201663A1 (en) * 2007-04-16 2008-10-30 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP3211001B1 (en) * 2010-12-22 2020-10-07 The Board of Trustees of the Leland Stanford Junior University Superagonists and antagonists of interleukin-2
TWI755579B (zh) 2013-02-26 2022-02-21 南韓商韓美藥品股份有限公司 新穎胰島素類似物及其用途
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
MA43289B1 (fr) 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Insuline à action prolongée et utilisation associée
EP3134102B1 (en) * 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
SG11201702558VA (en) 2014-10-21 2017-05-30 Sciclone Pharmaceuticals Inc Treatment of cancer with immune stimulators
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
KR20160134989A (ko) 2015-05-14 2016-11-24 순천향대학교 산학협력단 인간 인터류킨-2 단백질을 포함하는 약학조성물
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
EP3589373A4 (en) * 2017-03-03 2020-12-23 Obsidian Therapeutics, Inc. COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
EP3688036A4 (en) * 2017-09-25 2021-06-23 Dingfu Biotarget Co., Ltd PROTEINOUS HETERODIMER AND USE OF IT
US10946068B2 (en) * 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN112105632A (zh) 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
CN108503714A (zh) * 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
EP3794024B1 (en) * 2018-05-14 2023-05-10 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3102829A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CN112771072A (zh) * 2018-07-24 2021-05-07 生物技术Rna制药有限公司 Il2激动剂
BR112020015030A2 (pt) * 2018-09-17 2021-03-16 Gi Innovation, Inc. Proteína de fusão compreendendo a proteína il-2 e a proteína cd80 e uso da mesma
TWI791894B (zh) * 2018-09-21 2023-02-11 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途
KR20210092769A (ko) * 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NOVEL IMMUNOSUPRESSIVE INTERLEUKIN 2
CN111944036A (zh) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN114478743A (zh) 2019-12-17 2022-05-13 北京志道生物科技有限公司 白介素-2衍生物
JP2023525200A (ja) * 2020-03-05 2023-06-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 設計されたｉｌ－２変異型

Also Published As

Publication number Publication date
AR121713A1 (es) 2022-06-29
ZA202209565B (en) 2023-12-20
KR20210122200A (ko) 2021-10-08
AU2021202825A1 (en) 2021-10-14
PE20221759A1 (es) 2022-11-11
EP4130027A1 (en) 2023-02-08
AU2021202825B2 (en) 2022-06-30
JP2023515247A (ja) 2023-04-12
IL295826A (en) 2022-10-01
US20230124171A1 (en) 2023-04-20
US20230348550A1 (en) 2023-11-02
WO2021201615A1 (ko) 2021-10-07
KR102545250B1 (ko) 2023-06-21
CN115427437A (zh) 2022-12-02
CA3169564A1 (en) 2021-10-07
TW202204387A (zh) 2022-02-01
US11746137B2 (en) 2023-09-05
KR20230088656A (ko) 2023-06-20
AU2022203841A1 (en) 2022-06-23
MX2022011893A (es) 2022-10-18
CN115427437B (zh) 2024-04-19
JP2024041747A (ja) 2024-03-27
CL2022002562A1 (es) 2023-03-17

Similar Documents

Publication Publication Date Title
BR112022018730A2 (pt) Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformante
MX2021008147A (es) Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.
MX2021006970A (es) Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina.
BR112017018251A2 (pt) vetores retrovirais e lentivirais
MX2015014608A (es) Novedosas moleculas de union biespecifica con actividad antitumoral.
BR112017013274A2 (pt) polipeptídeo e imunomodulação
BR112019005637A2 (pt) análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
BR112019008349A2 (pt) composição de peptídeos, e, utilização de uma composição.
BR112017011271A2 (pt) composição, polipeptídeo isolado, aditivo de ração animal, ração animal, métodos de melhoria de um ou mais parâmetros de desempenho de um animal, de solubilização de xilose de material à base de plantas, de liberação de amido de material à base de plantas, de melhoria do valor nutricional de uma ração animal, de preparação de uma ração animal e de produção do polipeptídeo, uso de uma composição, polinucleotídeo, construto de ácido nucleico ou vetor de expressão, e, célula hospedeira recombinante.
BR112017019625A2 (pt) udp-glicosiltransferases
EA201790934A1 (ru) ВАРИАНТЫ ИНТЕРФЕРОНА α2b
ES2678144T3 (es) Composiciones relacionadas con SAH y métodos de uso
BR112013009157A2 (pt) polipeptídeos com atividade de permease
NZ756224A (en) Polypeptide variants and uses thereof
BR112018008681A2 (pt) novos polipeptídeos com estabilidade proteolítica melhorada, e métodos para preparar e usar os mesmos
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico
MX2022016532A (es) Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.
AR111373A1 (es) Enzimas de lactasa con propiedades mejoradas
BR112016030950A2 (pt) polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
BR112014030440A8 (pt) método para preparar um alqueno monoinsaturado
EA202190240A1 (ru) Варианты рекомбинантного белка
BR112012011598A2 (pt) polipeptídeos de haemophilus parasuis e métodos de uso
PH12016500251B1 (en) Rail fastening system
BR112021018734A2 (pt) Receptores de células t e métodos de uso destes
BR112021012240A2 (pt) Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich